Method for predicting the risk of obesity in a subject
Subject matter of the present invention is a method for determining the fat processing activity and/or predicting the risk of obesity in a subject. The method involves determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from a subject; and correlating the determined level of pro-neurotensin or fragments thereof with fat processing activity and/or the risk of incidence of obesity in the subject, wherein an elevated level is indicative of enhanced fat processing activity and/or predictive for an enhanced risk of getting obesity.
1. A method for determining fat processing activity and/or for predicting risk of obesity in a subject comprising:
determining by an immunoassay a level of pro-neurotensin 1-117 (SEQ ID NO: 5) or a level of peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) in a sample of bodily fluid obtained from said subject;
correlating said level of pro-neurotensin 1-117 (SEQ ID NO: 5) or said level of peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) with fat processing activity and/or a risk of incidence of obesity in said subject, wherein a level above a threshold level is indicative of an enhanced fat processing activity and/or predictive for an enhanced risk of obesity, and
reducing said subject's fat uptake if said level of pro-neurotensin 1-117 (SEQ ID NO: 5) or said level of peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) is above said threshold level,
wherein said subject is not obese when said sample of bodily fluid is taken from said subject,
wherein the subject does not have metabolic syndrome, and
wherein said immunoassay comprises (i) contacting said sample with one or more antibodies, at least one of which is labelled, that specifically bind to an epitope within pro-neurotensin 1-117 (SEQ ID NO: 5), to form a complex between the antibody and pro-neurotensin 1-117 (SEQ ID NO: 5) or peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5), and (ii) quantitating the level of the thus-formed complex.
2. A method according to claim 1 , wherein said subject is a non-prediabetic subject.
3. A method according to claim 1 , wherein a fasting level of pro-neurotensin 1-117 (SEQ ID NO: 5) or of peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) is determined.
4. A method according to claim 1 , wherein the level of pro-neurotensin 1-117 (SEQ ID NO: 5) is determined.
5. A method according to claim 1 wherein the subject is non-diabetic with fasting whole blood glucose of less than 6.1 mmol/1 but more than 5.4 mmol/l.
6. A method according to claim 1 wherein the subject does not have cancer.
7. A method according to claim 1 wherein the subject has no history of diagnosis of an acute cardiovascular event when said sample of bodily fluid is taken from said subject wherein said cardiovascular event is selected from myocardial infarction, stroke, and acute heart failure.
8. A method according to claim 1 , wherein said subject is a subject with fasting whole blood glucose of less than 5.4 mmol/1.
9. A method according to claim 1 , wherein the risk of obesity is independent of a risk for contracting diabetes mellitus and/or metabolic syndrome.
10. A method according to claim 1 , wherein additionally at least one clinical parameter is determined in the subject selected from age, gender, systolic blood pressure, diastolic blood pressure, antihypertensive treatment (AHT), waist circumference, waist-hip-ratio, current smoker, diabetes heredity and previous cardiovascular disease (CVD).
11. The method according to claim 1 , wherein the sample is selected from a blood sample, a serum sample, a plasma sample, a cerebrospinal fluid sample, a saliva sample and a urine sample or an extract of any of the aforementioned samples.
12. A method according to claim 1 , wherein said method is performed more than once in order to monitor the risk of incidence of obesity.
13. A method according to claim 12 , wherein said monitoring is performed in order to evaluate a response of said subject to preventive and/or therapeutic measures taken.
14. A method according to claim 1 , wherein said method is performed in a plurality of subjects in order to stratify said subjects into risk groups.
15. A method according to claim 1 , wherein said threshold level is at least 60 pmol/L pro-neurotensin 1-117 (SEQ ID NO: 5).
16. A method according to claim 1 , wherein said threshold level is at least 90 pmol/L pro-neurotensin 1-117 (SEQ ID NO: 5).
17. A method according to claim 1 , wherein said threshold level is at least 123 pmol/L pro-neurotensin 1-117 (SEQ ID NO: 5).
18. A method according to claim 1 , wherein said threshold level is at least 180 pmol/L pro-neurotensin 1-117 (SEQ ID NO: 5).
19. A method according to claim 1 , wherein peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) are selected from peptides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 7.
20. A method for determining fat processing activity and/or for predicting risk of obesity in a subject comprising:
determining by an immunoassay a level of pro-neurotensin 1-117 (SEQ ID NO: 5) or a level of peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) in a non-fasting or fasting sample of bodily fluid obtained from said subject,
administering fat to said subject,
determining by an immunoassay a level of pro-neurotensin 1-117 (SEQ ID NO: 5) or a level of peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) in a sample of bodily fluid obtained from said subject after fat-uptake,
calculating a difference between said levels after and before fat-uptake,
correlating said difference between said levels after and before fat-uptake of pro-neurotensin 1-117 (SEQ ID NO: 5) or of said peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5) with fat processing activity and/or a risk of incidence of obesity in said subject, wherein a higher difference is more indicative of an enhanced fat processing activity and/or more predictive of an enhanced risk of obesity than a lower difference, and
reducing said subject's fat uptake if said higher difference is calculated;
wherein the subject is not obese when the samples of bodily fluid are taken from said subject, and wherein said immunoassay comprises (i) contacting said sample with one or more antibodies, at least one of which is labelled, that specifically bind to an epitope within pro-neurotensin 1-117 (SEQ ID NO: 5), to form a complex between the antibody and pro-neurotensin 1-117 (SEQ ID NO: 5) or peptides that comprise the amino acid sequence of pro-neurotensin 1-117 (SEQ ID NO: 5), and (ii) quantitating the level of the thus-formed complex.